Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Ratiometric activatable cell-penetrating peptides label pancreatic cancer, enabling fluorescence-guided surgery, which reduces metastases and recurrence in orthotopic mouse models.

Metildi CA, Felsen CN, Savariar EN, Nguyen QT, Kaushal S, Hoffman RM, Tsien RY, Bouvet M.

Ann Surg Oncol. 2015;22(6):2082-7. doi: 10.1245/s10434-014-4144-1. Epub 2014 Oct 16.

2.

A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.

Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy AM, Bouvet M, Kelber JA, Klemke RL.

Cancer Res. 2014 Nov 15;74(22):6671-81. doi: 10.1158/0008-5472.CAN-14-1031. Epub 2014 Sep 26.

3.

Advantages of fluorescence-guided laparoscopic surgery of pancreatic cancer labeled with fluorescent anti-carcinoembryonic antigen antibodies in an orthotopic mouse model.

Metildi CA, Kaushal S, Luiken GA, Hoffman RM, Bouvet M.

J Am Coll Surg. 2014 Jul;219(1):132-41. doi: 10.1016/j.jamcollsurg.2014.02.021. Epub 2014 Mar 2.

4.

Fluorescence-guided surgery with a fluorophore-conjugated antibody to carcinoembryonic antigen (CEA), that highlights the tumor, improves surgical resection and increases survival in orthotopic mouse models of human pancreatic cancer.

Metildi CA, Kaushal S, Pu M, Messer KA, Luiken GA, Moossa AR, Hoffman RM, Bouvet M.

Ann Surg Oncol. 2014 Apr;21(4):1405-11. doi: 10.1245/s10434-014-3495-y. Epub 2014 Feb 6.

5.

Successful fluorescence-guided surgery on human colon cancer patient-derived orthotopic xenograft mouse models using a fluorophore-conjugated anti-CEA antibody and a portable imaging system.

Hiroshima Y, Maawy A, Metildi CA, Zhang Y, Uehara F, Miwa S, Yano S, Sato S, Murakami T, Momiyama M, Chishima T, Tanaka K, Bouvet M, Endo I, Hoffman RM.

J Laparoendosc Adv Surg Tech A. 2014 Apr;24(4):241-7. doi: 10.1089/lap.2013.0418. Epub 2014 Feb 4.

6.

Fluorescently labeled chimeric anti-CEA antibody improves detection and resection of human colon cancer in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Metildi CA, Kaushal S, Luiken GA, Talamini MA, Hoffman RM, Bouvet M.

J Surg Oncol. 2014 Apr;109(5):451-8. doi: 10.1002/jso.23507. Epub 2013 Nov 19.

7.

Incidence and survival patterns of rare anal canal neoplasms using the surveillance epidemiology and end results registry.

Metildi C, McLemore EC, Tran T, Chang D, Cosman B, Ramamoorthy SL, Saltzstein SL, Sadler GR.

Am Surg. 2013 Oct;79(10):1068-74.

8.

In vivo fluorescence imaging of gastrointestinal stromal tumors using fluorophore-conjugated anti-KIT antibody.

Metildi CA, Tang CM, Kaushal S, Leonard SY, Magistri P, Tran Cao HS, Hoffman RM, Bouvet M, Sicklick JK.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S693-700. doi: 10.1245/s10434-013-3172-6. Epub 2013 Aug 14.

9.

In vivo serial selection of human pancreatic cancer cells in orthotopic mouse models produces high metastatic variants irrespective of Kras status.

Metildi CA, Kaushal S, Hoffman RM, Bouvet M.

J Surg Res. 2013 Sep;184(1):290-8. doi: 10.1016/j.jss.2013.03.049. Epub 2013 Apr 5.

10.

Fluorescence-guided surgery and fluorescence laparoscopy for gastrointestinal cancers in clinically-relevant mouse models.

Metildi CA, Hoffman RM, Bouvet M.

Gastroenterol Res Pract. 2013;2013:290634. doi: 10.1155/2013/290634. Epub 2013 Feb 19.

11.

Fluorescence-guided surgery of human colon cancer increases complete resection resulting in cures in an orthotopic nude mouse model.

Metildi CA, Kaushal S, Snyder CS, Hoffman RM, Bouvet M.

J Surg Res. 2013 Jan;179(1):87-93. doi: 10.1016/j.jss.2012.08.052. Epub 2012 Sep 7.

12.

Fluorescence-guided surgery allows for more complete resection of pancreatic cancer, resulting in longer disease-free survival compared with standard surgery in orthotopic mouse models.

Metildi CA, Kaushal S, Hardamon CR, Snyder CS, Pu M, Messer KS, Talamini MA, Hoffman RM, Bouvet M.

J Am Coll Surg. 2012 Jul;215(1):126-35; discussion 135-6. doi: 10.1016/j.jamcollsurg.2012.02.021. Epub 2012 May 24.

13.

KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.

Kelber JA, Reno T, Kaushal S, Metildi C, Wright T, Stoletov K, Weems JM, Park FD, Mose E, Wang Y, Hoffman RM, Lowy AM, Bouvet M, Klemke RL.

Cancer Res. 2012 May 15;72(10):2554-64. doi: 10.1158/0008-5472.CAN-11-3552.

14.

An LED light source and novel fluorophore combinations improve fluorescence laparoscopic detection of metastatic pancreatic cancer in orthotopic mouse models.

Metildi CA, Kaushal S, Lee C, Hardamon CR, Snyder CS, Luiken GA, Talamini MA, Hoffman RM, Bouvet M.

J Am Coll Surg. 2012 Jun;214(6):997-1007.e2. doi: 10.1016/j.jamcollsurg.2012.02.009. Epub 2012 Apr 27.

15.

Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer.

Tran Cao HS, Kaushal S, Metildi CA, Menen RS, Lee C, Snyder CS, Messer K, Pu M, Luiken GA, Talamini MA, Hoffman RM, Bouvet M.

Hepatogastroenterology. 2012 Sep;59(118):1994-9. doi: 10.5754/hge11836.

16.

Submillimeter-resolution fluorescence laparoscopy of pancreatic cancer in a carcinomatosis mouse model visualizes metastases not seen with standard laparoscopy.

Tran Cao HS, Kaushal S, Menen RS, Metildi CA, Lee C, Snyder CS, Talamini MA, Hoffman RM, Bouvet M.

J Laparoendosc Adv Surg Tech A. 2011 Jul-Aug;21(6):485-9. doi: 10.1089/lap.2011.0181. Epub 2011 Jun 23.

Supplemental Content

Loading ...
Support Center